MAGL Inhibitor

MAGL Inhibitors (75):

Cat. No.	Nombre del producto	Efecto	Pureza

HY-177534

MGL-IN-2	Inhibitor
MGL-IN-2 (Compound 1) is a MGL inhibitor with IC₅₀ values of 0.006 μM and 0.0121 μM for mutant MGL and wild-type MGL, respectively. MGL-IN-2 can be used in the research of metabolic diseases.

HY-162315

MAGL-IN-16	Inhibitor
MAGL-IN-16 (compound 27) is an oral active, selective and reversible MAGL inhibitor with the IC₅₀ value of 10.3 nM. MAGL-IN-16 can increase the level of 2-AG and shows antidepressant effect in mouse depressed model caused by chronic restraint stress.

HY-152152

JZP-MA-13	Inhibitor
JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC₅₀ of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6.

HY-150702

MAGLi 432	Inhibitor
MAGLi 432 is a non-covalent, potent, highly selective, and reversible MAGL inhibitor. MAGLi 432 binds with high affinity to the MAGL active site, with IC₅₀ values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme). MAGLi 432 can be used in the research of chronic inflammation, blood–brain barrier dysfunction, neurological disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.

HY-117722

JW 618	Inhibitor
JW 618 is a selective ABHD6 inhibitor, with IC₅₀s of 38 and 13 nM for mouse and rat ABHD6.

HY-175270

MAGL-IN-22	Inhibitor
MAGL-IN-22 (Compound 40) is a reversible, competitive, selective and BBB-penetrable MAGL inhibitor with an IC₅₀ of 0.34  μM for hMAGL. MAGL-IN-22 has significant antioxidant and anti-inflammatory activity, and activates the Nrf2 pathway and significantly inhibits NFκB-mediated inflammation, without inducing cytotoxic effects. MAGL-IN-22 can be used for neurodegenerative diseases, chronic pain and cancers research.

HY-143263

FAAH/MAGL-IN-1	Inhibitor
FAAH/MAGL-IN-1 (compound SIH 3) is a potent FAAH and MAGL inhibitor with IC₅₀s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain.

HY-103463

SA57	Inhibitor	≥99.0%
SA57 is a potent, selective FAAH inhibitor with IC₅₀s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC₅₀s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC₅₀ of 850 nM), but not other brain serine hydrolases.

HY-157038

MAGL-IN-8	Inhibitor
MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC₅₀ of 2.5 ± 0.4 nM for hMAGL.

HY-144375

Monoacylglycerol lipase inhibitor 1	Inhibitor
Monoacylglycerol lipase inhibitor 1 is a potent monoacylglycerol lipase inhibitor (compound 13).

HY-168459

MAGL-IN-21	Inhibitor
MAGL-IN-21 (Compound (S)-6) is a selective inhibitor for monoacylglycerol lipase (MAGL) with an IC₅₀ of 1.59 nM.

HY-143264

FAAH/MAGL-IN-2	Inhibitor
FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier FAAH and MAGL inhibitor with IC₅₀s of 11 nM and 36 nM (K_is of 28 nM and 60 nM), respectively . FAAH/MAGL-IN-2 has the potential to research neuropathic pain without causing locomotion impairment.

HY-110178

WWL123	Inhibitor	98.0%
WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy.

HY-120560

OMDM169	Inhibitor
OMDM169 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor with activity to increase 2-AG levels. OMDM169 exerts analgesic activity through indirect activation of cannabinoid receptors. The effective concentration of OMDM169 is 0.13 μM.

HY-120171

DH-376	Inhibitor
DH-376 is a potent diacylglycerol lipase inhibitor with pIC₅₀ values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice. DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-146341

FAAH-IN-5	Inhibitor
FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.

HY-124378

MAGL-IN-17	Inhibitor
MAGL-IN-17 (Compound ) is an inhibitor for MAGL with a K_i of 0.4 μM. MAGL-IN-17 inhibits mouse MAGL and rat MAGL with IC₅₀ of 0.18 and 0.24 μM. MAGL-IN-17 exhibits anti-inflammatory activity in mouse experimental autoimmune encephalitis models.

HY-162304

MAGL-IN-14	Inhibitor
MAGL-IN-14 (compound 2) is a potent inhibitor of MAGL, with IC₅₀ of 0.00289 μM and 0.002 μM in HEK293 and PC3 cells, respectively.

HY-168032

MAGL-IN-18	Inhibitor
MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 0.03 nM.

HY-145945

MAGL-IN-6	Inhibitor
MAGL-IN-6 is a potent MAGL inhibitor with an IC₅₀ of 4.71 nM. MAGL-IN-6 can be used for neurological disorders research (WO2020065613A1; example 234).

Name
E-mail *

	Sorry, but the email address you supplied was invalid.